Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A light in the dark-reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making.

Journal of thrombosis and haemostasis : JTH·2026

Same author

Validation of a whole blood coagulometer sensitive to the direct oral anticoagulants.

Scientific reports·2025

Same author

Outcomes of a proactive first responder system for out-of-hospital cardiac arrests.

Resuscitation·2024

Same author

Outcomes of Warfarin Home INR Monitoring vs Office-Based Monitoring: a Retrospective Claims-Based Analysis.

Journal of general internal medicine·2023

Same author

Comment on: 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.

Journal of the American Geriatrics Society·2023

Same author

Impact of Hospital-based Multidisciplinary Anticoagulation Stewardship Programs.

Archives of medical research·2022

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Warfarin versus new agents: interpreting the data.

¹Department of Medicine, Lenox Hill Hospital, New York, NY 10075, USA. jansell@lenoxhill.net

Hematology. American Society of Hematology. Education Program

|January 18, 2011

Summary

This summary is machine-generated.

Vitamin K antagonists are difficult to manage for stroke prevention in atrial fibrillation (AF). New oral anticoagulants show promise but have limitations, requiring careful consideration for patient care.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: Jun 5, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

Cardiology
Pharmacology
Internal Medicine

Background:

Stroke prevention in atrial fibrillation (AF) necessitates lifelong oral anticoagulation.
Vitamin K antagonists (VKAs) are effective but challenging to manage, leading to underuse.
Emerging novel oral anticoagulants (NOACs) offer alternative mechanisms of action.

Purpose of the Study:

To review the current landscape of oral anticoagulation for stroke prevention in AF.
To compare the efficacy and safety profiles of VKAs and NOACs.
To discuss the implications of NOACs for clinical practice and patient management.

Main Methods:

Review of Phase III clinical trial data for NOACs in AF stroke prevention.
Comparative analysis of VKA and NOAC characteristics, including efficacy, safety, and monitoring requirements.
Discussion of clinical considerations for transitioning between anticoagulant therapies.

Main Results:

Dabigatran etexilate (a direct thrombin inhibitor) demonstrates excellent stroke prevention outcomes in AF.
Oral Factor Xa inhibitors are in Phase III trials for AF, with promising results in other indications.
NOACs offer advantages such as short-acting, unmonitored administration but possess their own limitations and potential adverse effects.

Conclusions:

NOACs are poised to replace VKAs for stroke prevention in AF, but careful consideration of pros and cons is essential.
Physicians and patients must weigh the benefits and drawbacks of each anticoagulant class during treatment decisions.
The perceived "drawbacks" of VKAs may offer management advantages in certain AF patient populations.